Colistimethate Injection

Description

Product Description: Colistimethate Injection is an antibiotic medication used for the treatment of severe bacterial infections, particularly those caused by multidrug-resistant gram-negative bacteria. It belongs to the class of antibiotics known as polymyxins and is primarily effective against bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. Colistimethate Injection provides a valuable therapeutic option for patients with infections that are resistant to other antibiotics.

Indications and Usage: Colistimethate Injection is indicated for the treatment of severe bacterial infections caused by susceptible gram-negative bacteria, including infections of the respiratory tract, urinary tract, bloodstream, and other sites. It is particularly useful in the treatment of infections caused by multidrug-resistant organisms.

Dosage and Administration: Dosage and administration of Colistimethate Injection should be determined by a qualified healthcare professional based on factors such as the severity of the infection, the patient's age and weight, renal function, and the susceptibility of the causative bacteria. It is typically administered intravenously over a period of 30 to 60 minutes.

Dosage Forms and Strengths: Colistimethate Injection is available as a sterile powder for reconstitution in vials containing various strengths, typically ranging from 1 million units to 3 million units per vial.

Contraindications: Colistimethate Injection is contraindicated in patients with a known hypersensitivity to colistimethate or any component of the formulation. It should not be used in patients with a history of severe allergic reactions to polymyxins.

Warnings and Precautions: Serious adverse reactions, including nephrotoxicity and neurotoxicity, have been reported with the use of colistimethate. It should be used with caution in patients with renal impairment or pre-existing neurologic conditions. Regular monitoring of renal function and neurologic status is recommended during treatment.

Adverse Reactions/Side Effects: Common adverse reactions associated with colistimethate include nephrotoxicity, neurotoxicity, and gastrointestinal disturbances such as nausea and vomiting. Other adverse effects may include hypersensitivity reactions and superinfection with resistant organisms.

Drug Interactions: Colistimethate may interact with other medications, including nephrotoxic drugs such as aminoglycosides and vancomycin, which may potentiate the risk of renal toxicity. Concurrent use with other nephrotoxic agents should be avoided whenever possible.

Use In Specific Populations Description: Safety and efficacy of Colistimethate Injection in pediatric patients, pregnant women, and nursing mothers have not been established. Caution should be exercised when administering to these populations, and the potential risks and benefits should be carefully considered.

How Supplied/Storage and Handling: Colistimethate Injection is supplied as a sterile powder in single-dose vials. It should be stored at controlled room temperature (20°C to 25°C) and protected from light. Reconstituted solutions should be used immediately or stored under refrigeration for up to 24 hours.